New hope for Tough-to-Treat skin cancer: PTX-100 trial launches
Disease control
Recruiting now
This study tests a new drug called PTX-100 in people with a rare type of skin lymphoma (CTCL) that has come back or not responded to other treatments. About 115 adults will receive the drug through an IV for several cycles. The goal is to see if it can shrink or control the cance…
Phase: PHASE2 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated May 17, 2026 04:14 UTC